Security key
457637700
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM)
CUSIP: 457637700
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Shares, no par value
- Total 13F shares
- 48,870
- Total 13F value
- $226,645
- Share change
- +48,870
- SEC-reported price per share
- $4.87
- Number of holders
- 4
- Value change
- +$226,645
- Number of buys
- 4
- Shares outstanding
- 3,319,502
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
4
Top holders
5
INM full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2025
InMed Pharmaceuticals Inc. SEC filings
InMed Pharmaceuticals Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 457637700
Recent filing periods:
Ownership snapshot
Top reported holders of INM - InMed Pharmaceuticals Inc. - Common Shares, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
YA II PN, Ltd.
Disclosed value leader
AdvisorShares Investments...
Comparable rows
14/15
Latest evidence
31 Dec 2024
13D/G
13F
3/4/5
Lead comparable stake: 10%
1 rows are not safely comparable across share classes.
13D/G row: YA II PN, Ltd.
Showing 1-6 of 15 holder rows.
Quick read
YA II PN, Ltd. leads the comparable SEC ownership view at 10%.
14 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens YA II PN, Ltd.'s linked filing trail.
Comparable ownership
Top 5
YA II PN, Ltd.
10%
SABBY MANAGEMENT, LLC
4.9%
AdvisorShares Investments LLC
91%
UBS Group AG
26%
CITADEL ADVISORS LLC
7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| YA II PN, Ltd. |
13D/G
|
10%
|
$14,885
80,372 shares
|
$0 | 13 Dec 2024 |
| SABBY MANAGEMENT, LLC |
13D/G
|
4.9%
|
$12,647
36,135 shares
|
$0 | 31 Dec 2024 |
| AdvisorShares Investments LLC |
13F
Company
|
91%
|
$171,665
733,296 shares
|
— | 30 Sep 2024 |
| UBS Group AG |
13F
Company
|
26%
|
$50,253
212,039 shares
|
— | 30 Sep 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
7%
|
$13,266
56,666 shares
|
— | 30 Sep 2024 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
6.3%
|
$11,920
50,296 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
4
Shares
48,870
Rows available
4
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q4 2025 Across Filers
Q4 2025 holders
6
Q4 2024 holders
4
Holder diff
-2
| Investor | Q4 2025 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q4 2025 value | Q4 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend